Talzenna plus Xtandi improved total survival in HRR-deficient mCRPC by 14 months and lowered demise danger by 38%, per TALAPRO-2 trial information.
Amongst sufferers with metastatic castration-resistant prostate most cancers (mCRPC), new remaining total survival (OS) information from the TALAPRO-2 trial verify that the mix of Talzenna (talazoparib) plus Xtandi (enzalutamide) gives a major survival profit, in keeping with findings introduced on the 2025 Genitourinary Cancers Symposium.
The trial demonstrated an 8.8-month enchancment in median OS, with the mix remedy extending survival to 45.8 months in contrast with 37 months with Xtandi alone, representing a 20.4% discount within the danger of demise.
Sufferers with homologous recombination restore (HRR)-deficient tumors had a fair larger 38% discount within the danger of demise, translating to a 14-month OS enchancment. On this group, the median OS with Talzenna plus Xtandi was 45.1 months and 31.1 months within the placebo and Xtandi arm. Nevertheless, the profit prolonged past sufferers who have been HRR-deficient, as these with out DNA restore mutations additionally noticed an OS achieve of roughly 9 months.
“TALAPRO-2 is the primary PARP inhibitor plus [androgen receptor pathway inhibitor (ARPI)] mixture research to indicate not solely a statistically vital, but additionally a clinically significant enchancment in total survival in sufferers with metastatic CRPC in unselected and in HRR-deficient [patients],” Dr. Neeraj Agarwal, FASCO, professor of drugs, Presidential Endowed Chair of Most cancers Analysis, director, the Genitourinary Oncology Program, the Heart of Investigational Therapeutics, the Huntsman Most cancers Institute (HCI), College of Utah.
Glossary:
ECOG efficiency standing of 1 or decrease: sufferers are absolutely lively (0) or restricted in strenuous exercise however ambulatory and in a position to carry out mild work (1).
General survival (OS): time from remedy initiation to demise from any trigger.
Metastasis: unfold of most cancers from the first website to distant organs.
Castration-resistant: prostate most cancers that progresses regardless of androgen deprivation remedy.
HRR-deficient: tumors with homologous recombination restore gene mutations, affecting DNA restore.
PARP inhibitor plus androgen receptor pathway inhibitor (ARPI): mixture remedy concentrating on DNA restore and androgen signaling in prostate most cancers.
Radiographic progression-free survival (rPFS): time till radiographic illness development or demise.
Taking a look at OS in subgroups of sufferers with no alterations detected by each circulating tumor DNA and tumor tissue, these with no BRCA alterations detected had a median OS of 48.4 months within the Talzenna and Xtandi arm and 37.1 months within the placebo and Xtandi arm. For these with no HRR alterations detected, the median OS within the Talzenna plus Xtandi arm was 46.6 months and 37.4 months for these given placebo and Xtandi.
In sufferers with BRCA1/2 alterations, the median OS was not reached within the Talzenna plus Xtandi arm versus 28.5 months within the placebo plus Xtandi arm. For these with non-BRCA1/2 HRR alterations, the median OS was 42.4 versus 32.6 months.
The trial’s main finish level, radiographic progression-free survival (rPFS), additionally noticed a considerable enchancment. Sufferers receiving Talzenna plus Xtandi had a median rPFS of 33.1 months, in contrast with 19.5 months with Xtandi alone.
Within the HRR-deficient cohort, sufferers given Talzenna plus Xtandi had a median rPFS of 30.7 months, in contrast with 12.3 months with Xtandi alone.
For security, there have been no new security indicators seen after a further two years of follow-up in both affected person inhabitants. Whereas grade 3 (extreme) or 4 (life-threatening) anemia was the most typical aspect impact, occurring in 49% of sufferers within the unselected inhabitants and 43.4% within the HRR-deficient inhabitants, it was largely manageable with dose changes. Sufferers additionally reported that their high quality of life was maintained, even with the prolonged remedy period.
Within the unselected affected person inhabitants, the speed of discontinuation attributable to unwanted side effects was 21.6%, which was much like that seen within the main evaluation, and eight.5% of sufferers discontinued Talzenna remedy attributable to anemia. Within the HRR-deficient inhabitants, the speed of discontinuation of Talzenna attributable to unwanted side effects was 13.1% and 4.5% of sufferers discontinued remedy attributable to anemia.
General, these information help the broad use of this mixture in each HRR-deficient and non-deficient populations.
“We’re very inspired, very proud of these outcomes and in addition there have been no security indicators seen. So, we actually hope this mixture makes a distinction in our sufferers lives,” added Agarwal.
Background and Rationale of TALAPRO-2
The section 3, double-blind, placebo-controlled TALAPRO-2 trial was designed to check whether or not combining the PARP inhibitor Talzenna with Xtandi may present longer-lasting illness management and enhance survival outcomes in sufferers with HRR gene-mutated mCRPC in contrast with placebo plus Xtandi.
Male sufferers aged 18 and older have been eligible to enroll within the research if that they had progressive illness at research entry, an ECOG efficiency standing of 1 or decrease, and a life expectancy of no less than 12 months. Those that had been beforehand handled with a second-generation ARPI, PARP inhibitor, cyclophosphamide or mitoxantrone for prostate most cancers; clinically vital heart problems; or vital renal or hepatic dysfunction have been ineligible for participation.
A complete of 805 sufferers have been randomly assigned in cohort 1 to obtain Talzenna 0.5 milligrams (mg) with Xtandi 160 mg per day (402 sufferers) or placebo and Xtandi 160 mg per day (403 sufferers). Randomization was stratified by HRR gene alteration standing. The research’s main finish level was rPFS.
100% of sufferers underwent potential tumor tissue testing earlier than enrollment. On this cohort, 20% of sufferers have been discovered to have HRR alterations. For particular gene alterations, BRCA1, BRCA2, ATM and CDK12 mutations have been evenly distributed between the remedy arms. Notably, BRCA1 and BRCA2 alterations have been current in roughly 7% of sufferers.
In June 2023, the Xtandi mixture for the remedy of HRR gene-mutant mCRPC, supported by information from TALAPRO-2. The information the FDA thought of on the time confirmed that the mix led to a 55% discount within the danger of illness development or demise. The median rPFS on the time was not reached with Talzenna and Xtandi versus 21.9 months with placebo plus Xtandi.
References:
“Last total survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line (1L) remedy in sufferers (pts) with homologous recombination restore (HRR)-deficient metastatic castration-resistant prostate most cancers (mCRPC) within the section 3 TALAPRO-2 trial.” By Dr. Karim Fizazi, et al. J Clin Oncol.
“Last total survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line remedy in unselected sufferers with metastatic castration-resistant prostate most cancers (mCRPC) within the section 3 TALAPRO-2 trial,” by Dr. Neeraj Agarwal et al. J Clin Oncol.
“Talazoparib plus enzalutamide in males with first-line metastatic castration-resistant prostate most cancers (TALAPRO-2): a randomised, placebo-controlled, section 3 trial,” by Dr. Neeraj Agarwal, et al. Lancet.
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
